SECURITIESFORM AND EXCHANGE COMMISSION8-K

SecuritiesItem registered7.01 pursuantRegulation toFD Section 12(b) of the Act:Disclosure.

EmergingItem growth9.01 company ☒Financial Statements and Exhibits.

UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

~~WASHINGTON,~~CURRENT ~~D.C. 20549~~REPORT

~~FORM~~Pursuant ~~8-K~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~CURRENT~~Date ~~REPORT~~of Report (Date of earliest event reported): October 28, 2025

~~Pursuant~~VOR toBIOPHARMA ~~Section 13 or 15(d)~~INC.

(Exact name of ~~the~~Registrant ~~Securities~~as ~~Exchange~~Specified ~~Act~~in ofIts ~~1934~~Charter)

Date of Report (Date of earliest event reported): September 17, 2025


Delaware	001-39979	81-1591163
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

500 Boylston Street, Suite 1350
Boston, Massachusetts		02116
(Address of Principal Executive Offices)		(Zip Code)

~~Vor~~Registrant’s ~~Biopharma~~Telephone ~~Inc.~~Number, Including Area Code: 617 655-6580

(~~Exact~~Former ~~name~~Name ofor ~~registrant~~Former asAddress, ~~specified~~if inChanged ~~its~~Since ~~Charter~~Last Report)

Delaware		001-39979		81-1591163
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

500 Boylston Street
Suite 1350
Boston, Massachusetts		02116
(Address of principal executive offices)		(Zip Code)

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~Registrant’s~~☐Soliciting ~~telephone~~material ~~number,~~pursuant ~~including~~to ~~area~~Rule ~~code:~~14a-12 under the Exchange Act (~~617)~~17 ~~655~~CFR 240.14a-~~6580~~12)

~~Not~~☐Pre-commencement ~~Applicable~~communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~(Former~~☐Pre-commencement ~~name~~communications orpursuant ~~former~~to ~~address,~~Rule if13e-4(c) ~~changed~~under ~~since~~the ~~last~~Exchange ~~report~~Act (17 CFR 240.13e-4(c))

~~Check~~Securities ~~the~~registered ~~appropriate~~pursuant ~~box below if the Form 8-K filing is intended~~ to ~~simultaneously~~Section ~~satisfy~~12(b) ~~the filing obligation~~ of the ~~registrant under any of the following provisions (see General Instructions A.2. below)~~Act:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	VOR	Nasdaq Global Select Market

☐Indicate ~~Soliciting~~by ~~material~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~14a~~405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-122 ~~under~~of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 (§ 240.~~14a~~12b-122 of this chapter).

☐Emerging ~~Pre-commencement~~growth ~~communications~~company ~~pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))~~☒

☐If ~~Pre-commencement~~an ~~communications~~emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to ~~Rule~~Section ~~13e-4~~13(ca) ~~under~~of the Exchange Act ~~(17 CFR 240~~.~~13e-4(c))~~ ☐

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		VOR		Nasdaq Global Select Market

On October 28, 2025, Vor Biopharma Inc. hosted a webcast to discuss late-breaking 48-week Phase 3 clinical trial data from China for telitacicept in primary Sjögren’s disease. A copy of the presentation used during the webcast is furnished as Exhibit 99.1.

~~Indicate~~The byinformation ~~check~~contained ~~mark~~in ~~whether~~this ~~the~~Current ~~registrant~~Report on Form 8-K, including Exhibit 99.1, attached hereto, is anbeing ~~emerging~~furnished ~~growth~~and ~~company~~shall asnot ~~defined~~be indeemed ~~Rule~~"filed" ~~405~~for purposes of Section 18 of the Securities Exchange Act of ~~1933~~1934, ~~(§230.405~~as ofamended ~~this~~(the ~~chapter~~"Exchange Act"), orand ~~Rule~~shall ~~12b-2~~not ofbe deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, ofexcept ~~1934~~as ~~(§240.12b-2~~expressly ofset ~~this~~forth ~~chapter)~~by specific reference in such filing.

Date: September 17, 2025

Vor Biopharma Inc.

/s/ Jean-Paul Kress

Jean-Paul Kress

Chief Executive Officer

IfExhibit an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActNo. ☐ Description

~~Item~~99.1 48-week Phase 3~~.03~~ ~~Material~~Clinical ~~Modification~~Trial toData ~~Rights~~from ofChina ~~Security~~for ~~Holders.~~Telitacicept in Primary Sjögren's Disease

On104 Cover ~~September 17,~~Page ~~2025,~~Interactive ~~Vor~~Data ~~Biopharma~~File ~~Inc.~~ (~~the~~embedded ~~“Company”)~~within ~~filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with~~ the ~~Secretary~~Inline ofXBRL ~~State of the State of Delaware to effect a reverse stock split at a ratio of 1-for-20 (the “Charter Amendment”~~document)~~. The Charter Amendment was authorized by the stockholders of the Company at the Company’s Special Meeting of Stockholders held on August 25, 2025.~~

Pursuant to the Charter Amendment, effective at 5:00 p.m. Eastern Time on September 18, 2025 (the “Effective Time”), every 20 shares of the Company’s issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in the par value per share. As a result of the reverse stock split, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise or vesting of all stock options and warrants outstanding at the Effective Time, which will result in a proportional decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise of such stock options and warrants, and a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company’s 2015 Stock Incentive Plan, Amended and Restated 2021 Equity Incentive Plan, 2021 Employee Stock Purchase Plan and 2023 Inducement Plan immediately prior to the Effective Time will be reduced proportionately. SIGNATURES

NoPursuant ~~fractional~~to ~~shares~~the ~~will~~requirements ~~be issued as a result~~ of the ~~reverse~~Securities ~~stock~~Exchange ~~split.~~Act ~~Stockholders~~ of ~~record~~1934, ~~who~~the ~~would~~registrant ~~otherwise~~has beduly ~~entitled~~caused tothis ~~receive~~report ato ~~fractional~~be ~~share~~signed ~~will~~on ~~receive~~its abehalf ~~cash~~by ~~payment in lieu thereof. The reverse stock split will affect all stockholders proportionately and will not affect any stockholder’s percentage ownership of~~ the ~~Company’s~~undersigned ~~common~~hereunto ~~stock~~duly ~~(except to the extent that the reverse stock split results in any stockholder owning only a fractional share)~~authorized.

The Company’s common stock will begin trading on The Nasdaq Global Select Market on a split-adjusted basis when the market opens on September 19, 2025. The new CUSIP number for the Company’s common stock following the reverse stock split will be 929033207.


			Vor Biopharma Inc.

Date:	October 28, 2025	By:	/s/ Jean-Paul Kress
			Jean-Paul Kress Chief Executive Officer

As of September 16, 2025, there were 136,822,693 shares of common stock outstanding. Immediately following the reverse stock split, there will be approximately 6,841,134 shares of common stock outstanding (subject to adjustment due to the effect of cashing out fractional shares as described above).

A copy of the Charter Amendment is filed with this report as Exhibit 3.1.

Item 8.01 Other Events.

The information contained in Item 3.03 of this Current Report on Form 8-K is hereby incorporated by reference.

The Company has registration statements on Form S-3 (File No. 333-268798, 333-284380 and 333-285969) and registration statements on Form S-8 (File No. 333-252908, 333-263540, 333-270789, 333-274275, 333-278117 and 333-285971) on file with the Securities and Exchange Commission (the “Commission”). Commission regulations permit the Company to incorporate by reference future filings made with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offerings covered by registration statements filed on Form S-3 or Form S-8. The information incorporated by reference is considered to be part of the prospectus included within each of those registration statements. Information in this Item 8.01 of this Current Report on Form 8-K is therefore intended to be automatically incorporated by reference into each of the active registration statements listed above, thereby amending them. Pursuant to Rule 416(b) under the Securities Act, the amount of undistributed shares of Common Stock deemed to be covered by the effective registration statements of the Company described above are proportionately reduced as of the Effective Time to give effect to the Reverse Stock Split.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
3.1		Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Vor Biopharma Inc.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing Compare · Vor Biopharma Inc.